October 19, 2017 — This is a big week for semaglutide – a promising cousin of liraglutide. Research is ongoing to figure out just how good it will be in both type 2 diabetes and obesity. And the milestones this week were all about diabetes. But you can find some encouragement for the obesity indication, too. Unanimous Support from FDA’s […]
August 28, 2017 — It’s official as of Friday. Liraglutide (Victoza) is not only for treating type 2 diabetes and obesity. FDA now says it also effectively prevents heart attacks, strokes, and cardiovascular deaths. This new information applies to people taking it for diabetes who also have heart disease. A Dramatic, Ongoing Shift in Diabetes Care This news represents […]
May 26, 2013 — The Danish maker of diabetes drugs, Novo Nordisk, said this week that their new obesity drug, liraglutide, could be ready by the end of 2014. Some business analysts are skeptical about the commercial potential of liraglutide in obesity because of modest efficacy — a view that the company rejects. In new clinical trial results from […]
